Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 7124
Gene Symbol: TNF
TNF
0.070 GeneticVariation disease BEFREE Single nucleotide polymorphism (SNP) of the TNF-α promoter region can potentially affect the function or expression of this cytokine, and thus modulate the risk of occurrence and intensity of OM and shortening of overall survival (OS). 31076897 2020
Entrez Id: 213
Gene Symbol: ALB
ALB
0.030 Biomarker disease BEFREE The patients' age, sex, body mass index, primary site, diabetes, serum albumin, creatinine, hemoglobin, leukocyte and lymphocyte, concurrent cisplatin or cetuximab, method of radiation, total radiation dose, feeding route, use of spacers, pilocarpine hydrochloride, and corticosteroid ointment were examined, and the associations of each variable with oral mucositis and candidiasis were analyzed by multivariate Cox regression analysis. 31177394 2020
Entrez Id: 57822
Gene Symbol: GRHL3
GRHL3
0.010 Biomarker disease BEFREE Although the primary endpoint was not met, the positive trends of OM-associated outcomes suggest that the novel mucoadhesive tablet delivery of clonidine might favorably affect the course and severity of CRT-induced SOM and support further evaluation. 31669562 2020
Entrez Id: 2252
Gene Symbol: FGF7
FGF7
0.060 Biomarker disease BEFREE The recombinant human truncated Keratinocyte growth factor (Palifermin) is the only FDA approved medicine for the treatment of oral mucositis. 30999249 2019
Entrez Id: 2475
Gene Symbol: MTOR
MTOR
0.060 GeneticVariation disease BEFREE Regarding safety, compared with patients who did not receive mTOR inhibitors, those who did had a higher risk of suffering stomatitis (RR = 3.20, 95% CI = 1.49,6.86, P = 0.003). 30760308 2019
Entrez Id: 2475
Gene Symbol: MTOR
MTOR
0.060 Biomarker disease BEFREE Prophylactic use of steroid mouth rinse provides a cost-effective option that substantially decreases the incidence and severity of mammalian target of rapamycin (mTOR) inhibitor-associated stomatitis and related oral AEs as well as the need for dose modification in MBC patients undergoing treatment with an mTOR inhibitor. 30833486 2019
Entrez Id: 146059
Gene Symbol: CDAN1
CDAN1
0.020 Biomarker disease BEFREE One DLT (anorexia and stomatitis, respectively) occurred with each of regimens 2 and 3. 29995287 2019
Entrez Id: 590
Gene Symbol: BCHE
BCHE
0.010 AlteredExpression disease BEFREE Grade 1-2 adverse events occurred in 12 patients and included mild transient stomatitis (2 cases), worsening of infantile acne (1 case), increases of serum cholesterol and triglycerides (4 cases), changes in serum phosphate levels (2 cases), increase of cholinesterase (2 cases), transient neutropenia (2 cases), transient anemia (1 case), transient lymphopenia (1 case) and recurrent infections (7 cases). 31053163 2019
Entrez Id: 841
Gene Symbol: CASP8
CASP8
0.010 Biomarker disease BEFREE Their data have shown that Gag-CASP8-VLPs, pseudotyped by the stomatitis virus G protein (VSV-G), can efficiently enter and deliver active CASP8 into breast cancer cells, leading to massive cell apoptosis and death. 30620218 2019
Entrez Id: 26273
Gene Symbol: FBXO3
FBXO3
0.010 GeneticVariation disease BEFREE The incidences of diarrhea and severe oral mucositis within the first 30 days post-transplantation were lower in the FBA group [(28.57% versus 65.45%; P < 0.001) (51.79% versus 70.91%; P = 0.039)]. 30337697 2019
Entrez Id: 406985
Gene Symbol: MIR200C
MIR200C
0.010 Biomarker disease BEFREE miR-200c Modulates the Pathogenesis of Radiation-Induced Oral Mucositis. 31346357 2019
Entrez Id: 4092
Gene Symbol: SMAD7
SMAD7
0.010 Biomarker disease BEFREE Our results suggest that short-course Tat-Smad7 application to oral mucositis promotes its healing but does not compromise the cytotoxic effect of RT on oral cancer and has context-specific effects on oral mucosa versus oral cancer. 30185419 2019
Entrez Id: 5175
Gene Symbol: PECAM1
PECAM1
0.010 Biomarker disease BEFREE Immunohistochemistry was used for angiogenesis (CD31) and transforming growth factor beta 1 (TGF-β1) analysis.On Day 5, all groups exhibited OM. 30672024 2019
Entrez Id: 29126
Gene Symbol: CD274
CD274
0.010 Biomarker disease BEFREE Compared with patients receiving chemotherapy, PD-1/PD-L1 inhibitor treated patients had higher risk of developing rash (RR = 1.84), pruritus (RR = 3.74) and vitiligo (RR = 9.54), and also lower risk in developing mucosal inflammation (RR = 0.26), stomatitis (RR = 0.26), and alopecia (RR = 0.03). 31096532 2019
Entrez Id: 7040
Gene Symbol: TGFB1
TGFB1
0.010 Biomarker disease BEFREE Immunohistochemistry was used for angiogenesis (CD31) and transforming growth factor beta 1 (TGF-β1) analysis.On Day 5, all groups exhibited OM. 30672024 2019
Entrez Id: 8549
Gene Symbol: LGR5
LGR5
0.010 Biomarker disease BEFREE Oral mucositis (OM) was induced by IR of the oral region of <i>Lgr5-lacZ</i> transgenic mice. 31497199 2019
Entrez Id: 83985
Gene Symbol: SPNS1
SPNS1
0.010 Biomarker disease BEFREE These studies used several classifications for OM (RTOG/EORTC, WHO, NCI-CTC) and pain (NRS, VAS and modified VAS). 31092370 2019
Entrez Id: 115482713
Gene Symbol: H3P10
H3P10
0.010 GeneticVariation disease BEFREE Across p16 status and smoking history subgroups, the most common treatment-related adverse events (AEs) were diarrhea (70-91%), rash/acne (72-84%), stomatitis (34-73%) with afatinib; and included stomatitis (39-100%), fatigue (22-50%), nausea (19-36%) with methotrexate. 31450171 2019
Entrez Id: 4677
Gene Symbol: NARS1
NARS1
0.010 Biomarker disease BEFREE These studies used several classifications for OM (RTOG/EORTC, WHO, NCI-CTC) and pain (NRS, VAS and modified VAS). 31092370 2019
Entrez Id: 4580
Gene Symbol: MTX1
MTX1
0.010 Biomarker disease BEFREE Even though future studies are necessary, higher cumulative Leucovorin doses and early initiation of Leucovorin after start of MTX seem to reduce oral mucositis. 31323533 2019
Entrez Id: 3146
Gene Symbol: HMGB1
HMGB1
0.010 Biomarker disease BEFREE In conclusion, our findings suggest that HMGB1 plays a key role in the pathogenesis of OM; therefore, blockade of HMGB1 by NecroX-7 may be a novel therapeutic strategy for OM. 30647411 2019
Entrez Id: 2875
Gene Symbol: GPT
GPT
0.010 GeneticVariation disease BEFREE The most common treatment-emergent adverse events were stomatitis (68% [Grade 3/4: 20%]), anemia (49% [Grade 3/4: 24%]) and alanine aminotransferase increase (41% [Grade 3/4: 4%]). 30904980 2019
Entrez Id: 1029
Gene Symbol: CDKN2A
CDKN2A
0.010 GeneticVariation disease BEFREE Across p16 status and smoking history subgroups, the most common treatment-related adverse events (AEs) were diarrhea (70-91%), rash/acne (72-84%), stomatitis (34-73%) with afatinib; and included stomatitis (39-100%), fatigue (22-50%), nausea (19-36%) with methotrexate. 31450171 2019
Entrez Id: 2099
Gene Symbol: ESR1
ESR1
0.010 Biomarker disease BEFREE Oral Care Evaluation to Prevent Oral Mucositis in Estrogen Receptor-Positive Metastatic Breast Cancer Patients Treated with Everolimus (Oral Care-BC): A Randomized Controlled Phase III Trial. 31594912 2019
Entrez Id: 23411
Gene Symbol: SIRT1
SIRT1
0.010 Biomarker disease BEFREE Inhibition of SIRT1 promotes taste bud stem cell survival and mitigates radiation-induced oral mucositis in mice. 31497199 2019